Furthermore, the combination trial of BXCL701, bempeg from Nektar and avelumab from Pfizer and Merck KGaA in second-line pancreatic cancer, will start following the completion of Nektar and Pfizer Phase Ib safety study of bempeg and avelumab and the outcome of that trial.
manufacturer: avelumab, Merck KGaA; manufacturer: avelumab, Pfizer